Close Menu

NEW YORK – In a document filed with the US Securities and Exchange Commission Thursday, Chembio Diagnostics reported its Emergency Use Authorization submission for a SARS-CoV-2 antibody test was deprioritized by the US Food and Drug Administration.

As a result, the agency will not review Chembio's EUA submission for the test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.